Holen Sie sich die Stockscreener-App
1.16
23.68%
-0.36
Handel nachbörslich:
1.10
-0.06
-5.17%
Schlusskurs vom Vortag:
$1.52
Offen:
$1.3
24-Stunden-Volumen:
3.25M
Relative Volume:
0.23
Marktkapitalisierung:
$8.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.4585
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
-1.69%
1M Leistung:
+71.85%
6M Leistung:
-37.30%
1J Leistung:
-35.73%
1-Tages-Spanne:
$1.1301
$1.3597
1-Wochen-Bereich:
$1.01
$1.77
52-Wochen-Spanne:
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.16 | 8.96M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com India
Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus.com
Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus.com
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Plus Therapeutics Doubles Survival Rates in Brain Cancer Trial, Raises $15M to Accelerate Growth - StockTitan
A Peek at Plus Therapeutics's Future Earnings - Benzinga
PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq
Plus Therapeutics Introduces REYOBIQ - citybiz
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView
Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com newswire
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com
FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks
FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India
Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan
Plus Therapeutics Sets Earnings Date: CNS Cancer Drug Developer to Report Q4 Results - StockTitan
Plus Therapeutics, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Plus Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital - Defense World
Plus Therapeutics stock gains on Boral Capital Buy rating By Investing.com - Investing.com South Africa
Plus Therapeutics stock gains on Boral Capital Buy rating - Investing.com India
D. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy Recommendation - Nasdaq
Plus Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Plus Therapeutics regains compliance with Nasdaq minimum stockholders’ equity requirement - MSN
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph
Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan
Plus Therapeutics Regains Nasdaq Compliance - Nasdaq
Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia
Plus Therapeutics regains Nasdaq compliance - Investing.com India
SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow
Plus Therapeutics regains Nasdaq compliance status - Investing.com India
Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement - GlobeNewswire
Plus Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Nasdaq
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):